title: Effects of Age on Glycemic Control in Patients With Type 2 Diabetes Treated with Insulin Detemir: A Post-Hoc Analysis of the PREDICTIVE™ 303 Study.
abstract: BACKGROUND
  This post-hoc sub-analysis investigated whether age (<65 years vs ≥65 years) affects glycemic control or hypoglycemic risk in patients with type 2 diabetes mellitus (T2DM) treated with once-daily insulin detemir.
  
  
  METHODS
  This was a 26-week, randomized, open-label, phase IV trial involving 2812 patients at 1083 predominantly primary care sites throughout the United States, of which 541 were designated for investigator-led insulin titration. The main efficacy measure was change in HbA1c (A1C) from baseline to Week 26. Patients were stratified by age in the sites designated for the investigator-led titration of insulin detemir. Safety measures included adverse events and change in hypoglycemic event rates from baseline to Week 26.
  
  
  RESULTS
  At Week 26, mean A1C and fasting plasma glucose decreased in both groups, but mean differences in change from baseline were not significant between groups. Within the group ≥65 years, significant reductions occurred for all daytime hypoglycemia, but there was no significant change from baseline in the other categories. In the group <65 years, reductions from baseline were significant for all hypoglycemic event categories. Changes in hypoglycemia rates from baseline were not significantly different between the age groups and there was no weight increase in either age group.
  
  
  CONCLUSIONS
  This analysis demonstrates that insulin detemir has similar efficacy and safety profiles for patients with T2DM ≥65 years compared with <65 years when treated via an investigator-led algorithm.
authors.affiliation: Iowa Diabetes and Endocrinology Research Center, 411 Laurel Street, Suite 3262, Des Moines, IA, 50314, USA. abhargava@iderc.com.
authors.forename: Anuj
authors.initials: A
authors.lastname: Bhargava
authors.affiliation: Novo Nordisk Inc., Princeton, NJ, USA.
authors.forename: Vicky
authors.initials: V
authors.lastname: Chan
authors.affiliation: Novo Nordisk Inc., Princeton, NJ, USA.
authors.forename: Edward S
authors.initials: ES
authors.lastname: Kimball
authors.affiliation: Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
authors.forename: David S
authors.initials: DS
authors.lastname: Oyer
mesh_terms: D000328:Adult; D000368:Aged; D000465:Algorithms; D001786:Blood Glucose / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000069057:Insulin Detemir / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014481:United States
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000069057:Insulin Detemir
references.citation: Diabetes Care. 2001 Nov;24(11):1936-40
references.pmid: 11679460
references.citation: Clin Interv Aging. 2014;9:1815-22
references.pmid: 25364239
references.citation: Diabetes Res Clin Pract. 2004 Nov;66(2):193-201
references.pmid: 15533587
references.citation: Diabetes Obes Metab. 2005 Jan;7(1):56-64
references.pmid: 15642076
references.citation: Diabetes Care. 2006 Jun;29(6):1269-74
references.pmid: 16732007
references.citation: Diabetes Obes Metab. 2007 Nov;9(6):902-13
references.pmid: 17924873
references.citation: J Am Geriatr Soc. 2007 Nov;55(11):1735-40
references.pmid: 17979896
references.citation: Arch Intern Med. 2008 Jan 28;168(2):192-9; discussion 199
references.pmid: 18227367
references.citation: Acta Diabetol. 2008 Mar;45(1):53-9
references.pmid: 18180864
references.citation: Diabetes Care. 2009 Feb;32(2):287-94
references.pmid: 19017771
references.citation: Adv Ther. 2009 Feb;26(2):194-207
references.pmid: 19259629
references.citation: Am J Med. 2009 Nov;122(11):1043-9
references.pmid: 19854333
references.citation: Am J Geriatr Pharmacother. 2009 Dec;7(6):324-42
references.pmid: 20129254
references.citation: Clin Ther. 2011 Jul;33(7):874-83
references.pmid: 21741089
references.citation: Diabetes Care. 2012 Jun;35(6):1364-79
references.pmid: 22517736
references.citation: J Am Med Dir Assoc. 2012 Jul;13(6):497-502
references.pmid: 22748719
references.citation: Diabetes Care. 2012 Dec;35(12):2650-64
references.pmid: 23100048
references.citation: J Am Geriatr Soc. 2012 Dec;60(12):2342-56
references.pmid: 23106132
references.citation: J Am Geriatr Soc. 2013 Apr;61(4):535-41
references.pmid: 23581911
references.citation: Endocr Pract. 2013 Mar-Apr;19(2):327-36
references.pmid: 23598536
references.citation: J Am Med Dir Assoc. 2013 Nov;14(11):801-8
references.pmid: 24074961
references.citation: J Am Med Dir Assoc. 2013 Nov;14(11):777-80
references.pmid: 24176597
references.citation: J Am Geriatr Soc. 2003 May;51(5 Suppl Guidelines):S265-80
references.pmid: 12694461